Whitehawk Therapeutics, Inc.
Clinical trials sponsored by Whitehawk Therapeutics, Inc., explained in plain language.
-
New hope for Hard-to-Treat cancers: targeted drug HWK-016 enters human testing
Disease control Recruiting nowThis early-phase study tests a new drug called HWK-016 in people with advanced ovarian or endometrial cancers that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to find the safest d…
Phase: PHASE1 • Sponsor: Whitehawk Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 01:46 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called HWK-007 in people with advanced solid tumors, such as certain ovarian, endometrial, and lung cancers. The drug is designed to target and attack cancer cells that have a specific marker (PTK7). The main goals are to find the safest do…
Phase: PHASE1 • Sponsor: Whitehawk Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 01:46 UTC